Your browser doesn't support javascript.
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
van Lierop, Zoë Ygj; Toorop, Alyssa A; van Ballegoij, Wouter Jc; Olde Dubbelink, Tom Bg; Strijbis, Eva Mm; de Jong, Brigit A; van Oosten, Bob W; Moraal, Bastiaan; Teunissen, Charlotte E; Uitdehaag, Bernard Mj; Killestein, Joep; Kempen, Zoé LE van.
  • van Lierop ZY; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Toorop AA; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • van Ballegoij WJ; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands/Department of Neurology, OLVG Hospital, Amsterdam, The Netherlands.
  • Olde Dubbelink TB; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands/Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Strijbis EM; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • de Jong BA; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • van Oosten BW; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Moraal B; Department of Radiology & Nuclear Medicine, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Teunissen CE; Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Uitdehaag BM; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Killestein J; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Kempen ZLV; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Mult Scler ; 28(7): 1121-1125, 2022 06.
Article in English | MEDLINE | ID: covidwho-1861984
ABSTRACT
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / COVID-19 / Multiple Sclerosis Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211028833

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / COVID-19 / Multiple Sclerosis Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211028833